REGENXBIO WKN: A140E0 ISIN: US75901B1070 Kürzel: RB0

Kurs zur REGENXBIO INC. DL-,0001 Aktie
21,78 USD
+7,93 %+1,60
28. May, 02:00:00 Uhr, Nasdaq
k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Börse: k.A.
k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Börse: k.A.
k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Börse: k.A.
k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Börse: k.A.
k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Börse: k.A.
k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Börse: k.A.
k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Börse: k.A.
k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Börse: k.A.
Anzeige
Alles ab 0 Euro pro Order. Dauerhaft.
Smartbroker
Summer.76
Summer.76, 4. Mai 22:19
REGENXBIO Reports First Quarter 2022 Financial Results and Recent Operational Highlights https://www.prnewswire.com/news-releases/regenxbio-reports-first-quarter-2022-financial-results-and-recent-operational-highlights-301540075.html
Summer.76
Summer.76, 2. Mär 5:53
REGENXBIO Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Operational Highlights https://www.prnewswire.com/news-releases/regenxbio-reports-fourth-quarter-and-full-year-2021-financial-results-and-recent-operational-highlights-301493248.html
Summer.76
Summer.76, 09.02.2022 19:06
REGENXBIO Presents Positive Initial Data from Phase I/II Trial of RGX-111 for the Treatment of Severe MPS I at 18th Annual WORLDSymposium™ 2022 https://www.prnewswire.com/news-releases/regenxbio-presents-positive-initial-data-from-phase-iii-trial-of-rgx-111-for-the-treatment-of-severe-mps-i-at-18th-annual-worldsymposium-2022-301478817.html
Summer.76
Summer.76, 22.11.2021 14:46
REGENXBIO Announces Orphan Drug Designation Granted to RGX-202, a Novel Gene Therapy Candidate for the Treatment of Duchenne Muscular Dystrophy https://www.prnewswire.com/news-releases/regenxbio-announces-orphan-drug-designation-granted-to-rgx-202-a-novel-gene-therapy-candidate-for-the-treatment-of-duchenne-muscular-dystrophy-301429654.html
Summer.76
Summer.76, 12.11.2021 22:55
REGENXBIO Presents Additional Positive Interim Data from Trials of RGX-314 in Wet AMD and Diabetic Retinopathy Using Suprachoroidal Delivery at AAO 2021 https://www.prnewswire.com/news-releases/regenxbio-presents-additional-positive-interim-data-from-trials-of-rgx-314-in-wet-amd-and-diabetic-retinopathy-using-suprachoroidal-delivery-at-aao-2021-301423126.html
Summer.76
Summer.76, 12.11.2021 22:54
RegenxBio’s deal with AbbVie just closed. It could mean more than $1B for the local company. https://www.bizjournals.com/washington/news/2021/11/12/regenxbio-abbvie-close-deal-eye-disease-treatment.html RegenxBio Inc. has closed a massive development and commercialization deal with Chicago’s AbbVie Inc., two months after announcing the agreement that stands to shovel move than $1 billion to the Rockville biotech. The partners said Tuesday they have closed that transaction, to bring to market the local gene therapy company’s treatment candidate for multiple eye diseases, now in clinical trials for wet age-related macular degeneration (AMD), diabetic retinopathy and other chronic retinal illnesses. Now, AbbVie (NYSE: ABBV) pays RegenxBio (NASDAQ: RGNX) $370 million upfront. But the deal also carries the potential for an additional $1.38 billion in development, regulatory and commercial milestones. ...
Summer.76
Summer.76, 08.11.2021 19:32
https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=847521
Summer.76
Summer.76, 02.11.2021 21:14
REGENXBIO Reports Third Quarter 2021 Financial Results and Operational https://www.prnewswire.com/news-releases/regenxbio-reports-third-quarter-2021-financial-results-and-operational-highlights-301414492.html
Summer.76
Summer.76, 02.11.2021 14:06
Regenxbio-Solid Biosciences' PDC releases white paper for AAV gene therapy development https://seekingalpha.com/news/3762777-regenxbio-solid-biosciences-pdc-releases-white-paper-for-aav-gene-therapy-development ... The draft white paper proposes a framework that can be applied to AAV gene therapies to facilitate the use of the accelerated approval pathway at the U.S. FDA. ...
Summer.76
Summer.76, 11.10.2021 10:56
REGENXBIO Presents Positive Initial Data from Phase II ALTITUDE™ Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery at American Society of Retina Specialists Annual Meeting https://finance.yahoo.com/news/regenxbio-presents-positive-initial-data-152300587.html
Kommentare
1 REGENXBIO INC. DL-,0001 Hauptdiskussion
Kursdetails
Geld (bid) 21,77 (3.400)
Brief (ask/offer) 21,78 (4.000)
Spread 0,05
Geh. Stück 406 Tsd.
Eröffnung 19,61
Vortag 20,18
Tageshoch 21,85
Tagestief 19,61
52W Hoch 46,46
52W Tief 18,69
Tagesvolumen
in EUR gehandelt 194 Stk
in USD gehandelt 406 Tsd. Stk
Gesamt 406 Tsd. Stk
Anzeige
Smartbroker
Der Broker von Deutschlands größter Finanzcommunity
Geld/Brief Kurse
Börse Geld Brief Zeit Volumen Kurs
Frankfurt 20,20 20,40 1653631282 27. May 18,60 EUR
Berlin 20,20 20,40 1653631386 27. May 18,60 EUR
Düsseldorf 19,80 20,80 1653672667 27. May 19,60 EUR
München 20,20 20,40 1653631379 27. May 18,60 EUR
Stuttgart 20,20 20,40 1653631258 27. May 18,60 EUR
Nasdaq 21,77 21,78 1653696000 02:00 405.603 Stk 21,78 USD
AMEX 1653696000 02:00 200 Stk 21,81 USD
Tradegate 20,20 20,40 1653683224 27. May 34 Stk 20,40 EUR
Lang & Schwarz 20,00 20,40 1653685088 27. May 160 Stk 20,20 EUR
London 1652896033 18. May 19,52 USD
Baader Bank 20,20 20,40 1653681421 27. May 20,30 EUR
TTMzero RT 1653634968 27. May 18,75 EUR
ges. 405.997 Stk
Realtime / Verzögert
Börsennotierung
Marktkapitalisierung in EUR
871,3 Mio.
Anzahl der Aktien
43,1 Mio.
Grundlegende Daten zur REGENXBIO INC. DL-,0001 Aktie
Finanzdaten 2018 2019 2020 2021 2022e 2023e 2024e
KUV - - - - - - -
Ergebnis je Aktie (bereinigt) - - - - - - -
Cashflow - - - - - - -
Eigenkapitalquote - - - - - - -
Verschuldungsgrad - - - - - - -
Eigenkapitalrendite - - - - - - -
Gesamtkapitalrendite - - - - - - -
EBITDA - - - - - - -
EBIT - - - - - - -
Fundamentaldaten 2018 2019 2020 2021 2022e 2023e 2024e
KCV - - - - - - -
Dividendenrendite - - - - - - -
Kurs-Gewinn-Verhältnis (KGV) - - - - - - -
Dividende je Aktie - - - - - - -
Bilanzdaten 2018 2019 2020 2021 2022e 2023e 2024e
Netto-Provisionsüberschuss - - - - - - -
Umsatzerlöse - - - - - - -
Ergebnis vor Steuern - - - - - - -
Steuern - - - - - - -
Ausschüttungssumme - - - - - - -
Nettoverzinsung - - - - - - -
Zinsertrag - - - - - - -
Gesamtertrag - - - - - - -
BörsennewsApp
BörsennewsApp im Google Play Store
BörsennewsApp im Apple Store

© 2022 börsennews.de

Daten und Kurse:

TTMzero RealTime

SIX Financial Information SIX Financial Information

Zeitverzögerung der Kursdaten: Deutsche Börsen +15 Min. NASDAQ +15 Min. NYSE +20 Min. AMEX +20 Min. Dow Jones +15 Min. Alle Angaben ohne Gewähr.